Report
Jacob Mekhael

Pharvaris Supportive data at C1-Inhibitor Deficiency and Angioedema Workshop

Pharvaris provided a summary of data that was presented at the C1-Inhibitor Deficiency and Angioedema Workshop, held 29 May – 1 June. The presentations continue to be supportive of deucrictibant's differentiated profile in HAE and included i) data that supports dual use of B2 antagonism for LTP and ODT in the same patients, ii) limited symptom recurrence showing durability of on-demand treatment, as well as iii) a novel biomarker assay that could help identify BK mediated angioedema. We reiterate our $32 TP and Buy rating.
Underlying
Pharvaris NV

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Jacob Mekhael

Other Reports on these Companies
Other Reports from KBC Securities
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch